Insider Profile · SEC Form 4 Activity · Trailing 90 Days

Harwin Peter Evan

Over the trailing 90 days, Harwin Peter Evan (Director at Oruka Therapeutics, Inc.) traded $719.7M of stock (net selling $679.7M) across 5 companies, per 12 SEC Form 4 transactions.

Role: Director
Companies: ORKA CBIO SYRE JBIO COGT
Window: Trailing 90 days · 12 transactions · CIK 1663607
Net activity: −$679.7M ($20.0M bought · $699.7M sold)
Source: Official filings on sec.gov ↗

By Company (Trailing 90 Days)

Symbol	Company	Txns	Bought	Sold	Net
SYRE	Spyre Therapeutics, Inc.	3	—	$399.7M	−$399.7M
ORKA	Oruka Therapeutics, Inc.	4	—	$300.0M	−$300.0M
CBIO	CRESCENT BIOPHARMA, INC.	3	$20.0M	—	$20.0M
JBIO	Jade Biosciences, Inc.	1	—	—	$0
COGT	Cogent Biosciences, Inc.	1	—	—	$0

Transactions (12)

Date	Symbol	Type	Shares	Value	Description
2026-07-16	CBIO	Buy	525.9K	$7.6M	Open market or private purchase
2026-07-16	CBIO	Buy	853.5K	$12.4M	Open market or private purchase
2026-07-01	ORKA	Sell	42.6K	$0	Conversion of derivative security
2026-07-01	ORKA	Sell	3.6M	$300.0M	Open market or private sale
2026-07-01	ORKA	Buy	3.6M	$0	Conversion of derivative security
2026-06-23	SYRE	Buy	666.7K	$0	Conversion of derivative security
2026-06-23	SYRE	Sell	4.7M	$399.7M	Open market or private sale
2026-06-23	SYRE	Sell	16.7K	$0	Conversion of derivative security
2026-06-09	JBIO	Buy	34.8K	$0	Grant, award or other acquisition
2026-06-09	COGT	Buy	17.9K	$0	Grant, award or other acquisition
2026-06-02	CBIO	Buy	11.1K	$0	Grant, award or other acquisition
2026-06-02	ORKA	Buy	9.1K	$0	Grant, award or other acquisition

Activity shown covers the trailing 90 days of SEC Form 4 filings. "Buy" and "sell" follow the SEC acquired/disposed codes and include compensation events (grants, option exercises, tax withholding) unless noted. Historical fact, not investment advice.

Follow Harwin's next move

Real-time Form 4 alerts, insider track records, and cluster detection — matched to your watchlist.

Start free